Brief: Index Pharmaceuticals Discontinues cobitolimod Phase III Program

Flerie AB

21/11/2023 19:33

Nov 21 (Reuters) - InDex Pharmaceuticals Holding AB
 INDEX.ST :
    * INDEX PHARMACEUTICALS DISCONTINUES COBITOLIMOD PHASE III
PROGRAM
    * INDEX PHARMACEUTICALS - INDEPENDENT DMC ADVISES THAT
COBITOLIMOD
IS UNLIKELY TO MEET PRIMARY ENDPOINT UPON COMPLETION OF
INDUCTION STUDY 1
    * INDEX PHARMACEUTICALS - DMC ADVISES COBITOLIMOD IS
UNLIKELY TO
MEET PRIMARY ENDPOINT UPON COMPLETION OF INDUCTION STUDY 1.
    * ADVICE TO STOP STUDY WAS NOT BASED ON SAFETY CONCERNS

Source text for Eikon:  ID:nWkr6bLKy3 
Further company coverage:  INDEX.ST 

 ((Reuters.Briefs@thomsonreuters.com;))